drugset / Trial / NCT07254637
Tocilizumab in Chronic Inflammatory CPPD Disease
Phase 2
Not yet recruiting
80 enrolled
Assistance Publique - Hôpitaux de Paris
Fresenius AG · collab
RandomizedParallel-groupSingle-blindTreatment
Summary
The aim of this clinical trial is to determine the efficacy of tocilizumab (an IL-6 inhibitor) in treatment-refractory chronic inflammatory forms of CPPD. The main questions this trial aims to answer are: * Can tocilizumab improve joint pain in patients with chronic inflammatory CPPD disease? * Does tocilizumab improve quality of life in patients with chronic inflammatory CPPD disease? Participants will receive a monthly infusion of tocilizumab or placebo for three months.
Timeline
- Start
- 2026-04
- Primary completion
- 2026-10
- Completion
- 2029-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tocilizumab | Monoclonal antibody | 8 mg/kg | Intravenous |